ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Acadia pulls plug on pimavanserin for adjunctive MDD
July 24, 2020Acadia Pharmaceuticals has terminated development of pimavanserin for major depressive disorder (MDD) after the drug failed to hit trials in this setting. -
ACADIA Pharma initiates Ph3 CLARITY Program with Pimavanserin for MDD
April 29, 2019According to the National Institute of Mental Health, MDD affects approximately 16 million adults in the U.S. with approximately 2.5 million adults treated with adjunctive therapy.
Pharma Sources Insight January 2025
